We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Migraine Drug Hits Phase III Primary Endpoint
Read MoreHide Full Article
Amgen Inc. (AMGN - Free Report) announced positive top-line data from a phase III study (ARISE) on calcitonin gene-related peptide (CGRP) receptor, erenumab (AMG 334), for the prevention of episodic migraine.
The multi-center, randomized, 12-week, double-blind, placebo-controlled study evaluated the safety and efficacy of erenumab in patients with episodic migraine. Data showed that patients, when treated with erenumab (70 mg), experienced a statistically significant 2.9-day reduction from baseline in monthly migraine days, in comparison to a 1.8-day reduction in the placebo arm at 12 weeks, thereby meeting the primary endpoint of the study. In addition, the safety profile of erenumab was found to be similar to placebo and consistent with previously reported studies.
Currently, additional analyses of these data are in progress and expected to be submitted at a future medical conference and for publication.
Earlier this year, positive data from a phase II study on erenumab for the prevention of chronic migraine were also announced. Meanwhile, the candidate is also being evaluated in a second phase III episodic migraine study (STRIVE), assessing both 70 mg and 140 mg doses for 24 weeks. The study is anticipated to be completed by the end of this year.
We note that, Amgen is developing erenumab in collaboration with Novartis AG (NVS - Free Report) , focused on the development and commercialization of treatments for migraine and Alzheimer's disease. For the migraine program, Amgen owns commercialization rights in the U.S., Canada and Japan, while Novartis has rights in Europe and Rest of World.
We note that several companies, including Teva Pharmaceutical Industries Limited (TEVA - Free Report) and Allergan plc among others, are developing migraine treatments targeting CGRP.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Amgen (AMGN) Migraine Drug Hits Phase III Primary Endpoint
Amgen Inc. (AMGN - Free Report) announced positive top-line data from a phase III study (ARISE) on calcitonin gene-related peptide (CGRP) receptor, erenumab (AMG 334), for the prevention of episodic migraine.
The multi-center, randomized, 12-week, double-blind, placebo-controlled study evaluated the safety and efficacy of erenumab in patients with episodic migraine. Data showed that patients, when treated with erenumab (70 mg), experienced a statistically significant 2.9-day reduction from baseline in monthly migraine days, in comparison to a 1.8-day reduction in the placebo arm at 12 weeks, thereby meeting the primary endpoint of the study. In addition, the safety profile of erenumab was found to be similar to placebo and consistent with previously reported studies.
Currently, additional analyses of these data are in progress and expected to be submitted at a future medical conference and for publication.
AMGEN INC Price
AMGEN INC Price | AMGEN INC Quote
Earlier this year, positive data from a phase II study on erenumab for the prevention of chronic migraine were also announced. Meanwhile, the candidate is also being evaluated in a second phase III episodic migraine study (STRIVE), assessing both 70 mg and 140 mg doses for 24 weeks. The study is anticipated to be completed by the end of this year.
We note that, Amgen is developing erenumab in collaboration with Novartis AG (NVS - Free Report) , focused on the development and commercialization of treatments for migraine and Alzheimer's disease. For the migraine program, Amgen owns commercialization rights in the U.S., Canada and Japan, while Novartis has rights in Europe and Rest of World.
We note that several companies, including Teva Pharmaceutical Industries Limited (TEVA - Free Report) and Allergan plc among others, are developing migraine treatments targeting CGRP.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>